Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1083 in Healthy Adults ≥50 Years
NCT06097273Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mCOMBRIAX in coronavirus disease 2019 (COVID-19), influenza, sponsored by Moderna Inc. Started Oct 2023; status: completed.
02
Drugs
mCOMBRIAX
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06097273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097273.